DNA and recombinant adenovirus serotype 35 and 5 preventive HIV-1 vaccines with Env A inserts elicit cross-clade binding and V1V2 antibodies

Ähnliche Einträge

• Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C.
  von: Jeff Alexander, et al.
  Veröffentlicht: (2013-01-01)
• Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin.
  von: Jeff Alexander, et al.
  Veröffentlicht: (2012-01-01)
• Passive Transfer of Immune Sera Induced by a Zika Virus-Like Particle Vaccine Protects AG129 Mice Against Lethal Zika Virus Challenge
  von: Diego Espinosa, et al.
  Veröffentlicht: (2018-01-01)
• Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges
  von: Sunil K. Khattar, et al.
  Veröffentlicht: (2015-09-01)
• DNA and recombinant adenovirus serotype 35 and 5 preventive HIV-1 vaccines with Env A inserts elicit cross-clade binding and V1V2 antibodies
  von: Fuchs JD, et al.
  Veröffentlicht: (2012-09-01)